Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

被引：1
|
作者：
Muggia, F.
Safra, T.
Borgato, L.
Gandhi, A.
Mancinc, G.
Gabizon, A.
Liebes, L.
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] IOV, Padua, Italy
[4] SZMC, Jerusalem, Israel
[5] NYU, Inst Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations
    Safra, T.
    Borgato, L.
    Nicoletto, M.
    Rolnitzky, L.
    Curtin, J.
    Geva, R.
    Peles, S.
    Grenader, T.
    Gabizon, A.
    Muggia, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer [REOC).
    Grenier, N
    Lebel, V
    Gill, M
    Mitchinson, K
    Foster, M
    Lewis, S
    Sebborn, K
    Rodgers, A
    Pouliot, JF
    Mullen, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 778S - 778S
  • [3] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [4] Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, Gurbuz
    Kucukzeybek, Yuksel
    Karabulut, Bulent
    Terek, Mustafa C.
    Uslu, Ruchan
    Sanli, Ulus A.
    Akman, Levent
    Ozsaran, Aydin
    Dikmen, Yilmaz
    Goker, Erdem
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [5] Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
    Muggia, F. M.
    Boyd, L.
    Liebes, L.
    Downey, A.
    Muller, C.
    Pothuri, B.
    Blank, S.
    Rutledge, T.
    Fishman, D.
    Verschraegen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer
    Kumar, Parag
    Caron, Whitney P.
    Song, Gina
    Gallagher, Katie
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER RESEARCH, 2012, 72
  • [7] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer.
    Caron, W. P.
    Lay, J. C.
    Fong, A. M.
    La-Beck, N. M.
    Newman, S. E.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Efficacy and toxicity of extended duration pegylated liposomal doxorubicin (PLD) in women with recurrent epithelial ovarian cancer
    Chambers, L. Moulton
    Pendlebury, A. B.
    Yao, M.
    Rose, P. G.
    DeBernardo, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 107 - 108
  • [9] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Zhen Yuan
    Ying Zhang
    Dongyan Cao
    Keng Shen
    Qingshui Li
    Guonan Zhang
    Xiaohua Wu
    Manhua Cui
    Ying Yue
    Wenjun Cheng
    Li Wang
    Pengpeng Qu
    Guangshi Tao
    Jianqing Hou
    Lixin Sun
    Yuanguang Meng
    Guiling Li
    Changzhong Li
    Huirong Shi
    Yaqing Chen
    Journal of Ovarian Research, 14
  • [10] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
12345